Empirical antifungal therapy in neutropaenic cancer patients with persistent fever

[1]  G. Verhoef,et al.  Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Thomas J Walsh,et al.  Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. , 2004, The New England journal of medicine.

[3]  J. Sierra,et al.  Low‐dose amphotericin b lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies – a randomized, controlled trial , 2004, European journal of haematology.

[4]  T. Calandra,et al.  Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .

[5]  E. Anaissie,et al.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. , 2002, The New England journal of medicine.

[6]  A. Schwarer,et al.  Intravenous and Oral Itraconazole versus Intravenous Amphotericin B Deoxycholate as Empirical Antifungal Therapy for Persistent Fever in Neutropenic Patients with Cancer Who Are Receiving Broad-Spectrum Antibacterial Therapy , 2001, Annals of Internal Medicine.

[7]  U. Eriksson,et al.  Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial , 2001, BMJ : British Medical Journal.

[8]  H. Kantarjian,et al.  Comparison of Amphotericin B Lipid Complex (ABLC) vs. AmBisome in the Treatment of Suspected or Documented Fungal Infections in Patients with Leukemia , 2001, Leukemia & lymphoma.

[9]  E. Anaissie,et al.  A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia , 2000 .

[10]  M. Territo,et al.  A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. , 2000, The American journal of medicine.

[11]  E. Anaissie,et al.  A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  T. Büchner,et al.  Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine. , 1999, Mycoses.

[13]  L. Bouzas,et al.  Comparison of the Toxicity of Amphotericin B in 5% Dextrose with That of Amphotericin B in Fat Emulsion in a Randomized Trial with Cancer Patients , 1999, Antimicrobial Agents and Chemotherapy.

[14]  R. Finberg,et al.  Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia , 1999 .

[15]  S. Khan,et al.  A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. , 1998, The American journal of medicine.

[16]  H. V. D. Lelie,et al.  Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia‐associated invasive fungal infections , 1998, British journal of haematology.

[17]  J. Wingard,et al.  Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  C. R. Pinkerton,et al.  A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients , 1997, British journal of haematology.

[19]  W. Leisenring,et al.  Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. , 1997, The Journal of infectious diseases.

[20]  C. Viscoli,et al.  Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. , 1996, European journal of cancer.

[21]  M. Kalin,et al.  Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever--preliminary observations from a pilot, exploratory study. , 1995, The Journal of infection.

[22]  O. Casasnovas,et al.  A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. , 1994, The Journal of antimicrobial chemotherapy.

[23]  J. Marie,et al.  Etude multicentrique randomisée fluconazole IV versus amphotéricine B IV chez le patient neutropénique et fébrile , 1993 .

[24]  D. Longo,et al.  Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study. , 1991, Archives of internal medicine.

[25]  J. V. D. van der Meer,et al.  The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. , 1991, The Journal of infection.

[26]  G. Bodey.  Fungal Infections in Cancer Patients , 1988, Annals of the New York Academy of Sciences.

[27]  L. Elting,et al.  Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients , 1987, Antimicrobial Agents and Chemotherapy.

[28]  W. Lee,et al.  Fungal infections in patients with acute leukemia. , 1982, The American journal of medicine.

[29]  F. Witebsky,et al.  Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. , 1982, The American journal of medicine.